

Unaudited Financial Statements for the Year Ended 30 September 2020

for

Biologica Limited

Contents of the Financial Statements
for the Year Ended 30 September 2020

| | Page |
|--|-------------|
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 3 |

Biologica Limited

Company Information
for the Year Ended 30 September 2020

DIRECTORS:

Dr R F Cox
Dr T Wolter-Cox

SECRETARY:

Dr R F Cox

REGISTERED OFFICE:

23 High Street
Upton
Northampton
Northamptonshire
NN5 4EN

REGISTERED NUMBER:

02603302

ACCOUNTANTS:

Peter Upton
Bridge House
2 Bridge Avenue
Maidenhead
Berkshire
SL6 1RR

Biologica Limited (Registered number: 02603302)**Balance Sheet**
30 September 2020

| | Notes | 30.9.20 £ | £ | 30.9.19 £ | £ |
|--|-------|--------------|----------|--------------|----------|
| FIXED ASSETS | | | | | |
| Intangible assets | 3 | - | - | - | - |
| Tangible assets | 4 | - | - | - | - |
| Investments | 5 | 59,814 | 59,814 | 59,814 | 59,814 |
| | | | 59,814 | | 59,814 |
| CURRENT ASSETS | | | | | |
| Cash at bank and in hand | | 279 | | 669 | |
| CREDITORS | | | | | |
| Amounts falling due within one year | 6 | 19,370 | | 19,370 | |
| NET CURRENT LIABILITIES | | | (19,091) | | (18,701) |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | | 40,723 | | 41,113 |
| CAPITAL AND RESERVES | | | | | |
| Called up share capital | 7 | | 2 | | 2 |
| Retained earnings | 8 | 40,721 | | 41,111 | |
| SHAREHOLDERS' FUNDS | | | 40,723 | | 41,113 |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the the Board of Directors and authorised for issue on 26 March 2021 and were signed on its behalf by:

Dr R F Cox - Director

Notes to the Financial Statements
for the Year Ended 30 September 2020

1. STATUTORY INFORMATION

Biologica Limited is a private company, limited by shares, registered in Not specified/Other. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 2000, is being amortised evenly over its estimated useful life of ten years.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| | |
|--------------------|-----|
| Computer equipment | 20% |
|--------------------|-----|

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**Notes to the Financial Statements - continued
for the Year Ended 30 September 2020**

3. INTANGIBLE FIXED ASSETS

| | |
|-----------------------|----------------|
| | Goodwill £ |
| COST | |
| At 1 October 2019 | |
| and 30 September 2020 | <u>100,000</u> |
| AMORTISATION | |
| At 1 October 2019 | |
| and 30 September 2020 | <u>100,000</u> |
| NET BOOK VALUE | |
| At 30 September 2020 | <u>-</u> |
| At 30 September 2019 | <u>-</u> |

4. TANGIBLE FIXED ASSETS

| | Fixtures and fittings £ | Office & sundry equipment £ | Totals £ |
|-----------------------|----------------------------------|--------------------------------------|---------------|
| COST | | | |
| At 1 October 2019 | | | |
| and 30 September 2020 | <u>676</u> | <u>13,055</u> | <u>13,731</u> |
| DEPRECIATION | | | |
| At 1 October 2019 | | | |
| and 30 September 2020 | <u>676</u> | <u>13,055</u> | <u>13,731</u> |
| NET BOOK VALUE | | | |
| At 30 September 2020 | <u>-</u> | <u>-</u> | <u>-</u> |
| At 30 September 2019 | <u>-</u> | <u>-</u> | <u>-</u> |

5. FIXED ASSET INVESTMENTS

Investments (neither listed nor unlisted) were as follows:

| | | |
|-------------------|---------------|---------------|
| | 30.9.20 | 30.9.19 |
| | £ | £ |
| TB related assets | <u>59,814</u> | <u>59,814</u> |

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

| | | |
|-----------------------------|---------------|---------------|
| | 30.9.20 | 30.9.19 |
| | £ | £ |
| Directors' current accounts | 19,010 | 19,010 |
| Accrued expenses | <u>360</u> | <u>360</u> |
| | <u>19,370</u> | <u>19,370</u> |

Notes to the Financial Statements - continued
for the Year Ended 30 September 2020

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number: Class:

2 Ordinary

Nominal
value:
£1

30.9.20
£
2

30.9.19
£
2

8. RESERVES

At 1 October 2019
Deficit for the year
At 30 September 2020

Retained
earnings
£

41,111
(390)
40,721

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.